Aquestive Therapeutics (NASDAQ:AQST) announced its earnings results on Thursday. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.35, MarketWatch Earnings reports. The firm had revenue of $16.82 million during the quarter, compared to analyst estimates of $17.05 million. Aquestive Therapeutics updated its FY 2019 guidance to EPS.
NASDAQ:AQST traded up $0.17 on Friday, hitting $6.54. 600 shares of the stock were exchanged, compared to its average volume of 114,662. Aquestive Therapeutics has a 52 week low of $5.60 and a 52 week high of $20.70. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.63 and a quick ratio of 3.42.
Large investors have recently made changes to their positions in the business. New York State Common Retirement Fund acquired a new position in shares of Aquestive Therapeutics during the 4th quarter worth about $28,000. Keybank National Association OH bought a new stake in Aquestive Therapeutics in the third quarter worth approximately $239,000. Bank of New York Mellon Corp bought a new stake in Aquestive Therapeutics in the fourth quarter worth approximately $108,000. Point72 Asset Management L.P. bought a new stake in Aquestive Therapeutics in the third quarter worth approximately $350,000. Finally, Millennium Management LLC bought a new stake in Aquestive Therapeutics in the fourth quarter worth approximately $145,000. 58.34% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4223260/aquestive-therapeutics-aqst-posts-quarterly-earnings-results.html.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.